Skip to main content
. Author manuscript; available in PMC: 2022 Aug 15.
Published in final edited form as: Cancer Res. 2022 Feb 15;82(4):648–664. doi: 10.1158/0008-5472.CAN-21-1705

Figure 6. O-glycosylation of the CDK4-Rb axis in TAFs modulates Palbociclib efficacy.

Figure 6.

A, Phase-contrast microcopy of TAFs:HCC827 cocultures treated with 10 μM DON, 1 μM palbociclib or a combination of both. White arrowheads show examples of TAFs that have gained an activated TCFs-like morphology. B, Force-directed layout of TAFs cocultures showing proliferative (upper gate) and non-proliferative (lower gate) TAFs and (C) bar graph quantification of percentage ratios relative to non-treated cocultures. Bar graph quantification showing all conditions of TAFs mono- and cocultures relative to untreated monoculture for (D) proliferative and (E) non-proliferative TAFs. Force-directed layout of HCC827 cocultures showing proliferative (left gate) and non-proliferative (right gate) cancer cells (F) and bar graph quantification of percentage ratios relative to non-treated cocultures. G, Bar graph quantification showing all conditions of HCC827 mono- and cocultures relative to non-treated monoculture for (H) proliferative and (I) non-proliferative cancer cells. Results are from two independent experiments with biological replicates combined (TAFs from specimens 1 and 3).